Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-70
SponsorUniversity of California, San Francisco
About this trial
Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test if a remote intervention can help participants improve remembering to take their HIV medications and reduce the HIV viral load among men living with HIV who use stimulants.
Eligibility criteria
Qualifiers
Prescribed antiretroviral therapy (ART) with a tenofovir-based regimen.
Documented virologic non-suppression, urine tenofovir testing without tenofovir detected, or self-reported adherence <100%.
Reports stimulant use.
Has a mailing address within the U.S.
Disqualifiers
Have any health condition that may interfere with participation or the ability to provide informed consent, including any debilitating or life-threatening conditions.
Not prescribed ART.
Unwilling to perform urine self-testing or to attend a local Quest site for viral load monitoring.
Unable to provide a hair sample of ~50-100 strands of hair that are non-gray, not bleached, and at least 1cm in length
Trial design
Treatments tested in this trial
- reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention
- urine tenofovir point-of-care self-test
Treatment groups
270 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of California, San Francisco
Lead sponsor
Florida International University
Collaborator
San Diego State University
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov